CLL is associated with an increased risk of infectious complications. Treatment with BTK or
BCL-2 inhibitors does not seem to increase significantly the risk of opportunistic infections …

Background Tuberculosis (TB) is a rare but potentially devastating complication in
hematopoietic stem cell transplantation (HSCT) recipients. Myelosuppression-related …

One-quarter of the world's population is infected with Mycobacterium tuberculosis (Mtb).
After initial exposure, more immune-competent persons develop asymptomatic latent …

High response rates in B-cell malignancies have been achieved with chimeric antigen
receptor (CAR) T-cell therapy. Emerging reports indicate a risk of active tuberculosis (TB) …

Background Identification of latent tuberculosis infection (LTBI) is a critical step of
tuberculosis surveillance, especially in low-incidence countries. However, it is limited to …

Immune checkpoints are crucial for regulating immune responses and maintaining self-
tolerance, as they play a pivotal role in preventing autoimmunity and facilitating tumor …

Nontuberculous mycobacteria (NTM) are ubiquitous environmental organisms and widely
distributed in water and soil [1]. In humans, NTM infections can be localized to the lungs, but …

Background The incidence of mycobacterial infections in patients with hematologic
malignancies and hematopoietic stem cell transplant (HSCT) recipients is increasing …

The diagnosis of nontuberculous mycobacterial infections is challenging in pediatric solid
organ transplant and hematopoietic cell transplant recipients due to the absence of specific …

Ibrutinib, a highly effective inhibitor of the Bruton tyrosine kinase, has significantly
transformed the therapeutic approach in chronic lymphocytic leukemia (CLL). Despite these …